Photo by Kost9n4 on Pixabay Boston Scientific (BSX) has lost a third of its value year-to-date, including a single-session drop of 9% on March 30. For a company with a multi-year track record of double-digit revenue growth, that's a significant drawdown. Is this a buying opportunity, or is the market correctly repricing a structurally weaker growth story? We unpack this below. Why Did BSX Fall Yesterday? The immediate trigger was CHAMPION-AF trial data for the Watchman FLX device. The trial met its end ...